Ribociclib: tested on its own

29 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast CancerNot yet recruitingNCT07630948Phase 4Report a problem
• Ribociclib for HR-positive HER2-negative Metastatic Breast CancerRecruitingNCT07164976Phase 1/2Report a problem
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsRecruitingNCT05452213Phase 4Report a problem
• Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based CohortsTerminatedNCT04657679Phase 4Results postedReport a problem
• A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation TherapyTerminatedNCT02607124Phase 1/2Results postedReport a problem
• LEE001 and Chemoembolization In Patients With Advanced Hepatocellular CarcinomaTerminatedNCT02524119Phase 2Results postedReport a problem
• Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginCompletedNCT02420691Phase 2Results postedReport a problem
• A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent ProgressionCompletedNCT02300987Phase 2Results postedReport a problem
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results postedReport a problem
• Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and NeuroblastomaTerminatedNCT01747876Phase 1Results postedReport a problem
• First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerCompletedNCT06375707Phase 2Report a problem
• Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast CancerActive, not recruitingNCT05996107Phase 1Report a problem
• Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)WithdrawnNCT05664893Phase 1/2Report a problem
• Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCActive, not recruitingNCT04055493Phase 3Report a problem
• Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer PatientsStatus unknownNCT03913234Phase 1/2Report a problem
• Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBCTerminatedNCT03905343Phase 3Report a problem
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerActive, not recruitingNCT03701334Phase 3Report a problem
• CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast CancerActive, not recruitingNCT03285412Phase 2Report a problem
• Impact of Ribociclib on Head and Neck Squamous Cell CancerTerminatedNCT03179956Early Phase 1Report a problem
• A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaStatus unknownNCT03096912Phase 2Report a problem
• Ribociclib (LEE011) Rollover Study for Continued AccessActive, not recruitingNCT02934568Phase 2Report a problem
• Ribociclib (LEE011) in Preoperative Glioma and Meningioma PatientsActive, not recruitingNCT02933736Early Phase 1Report a problem
• A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaStatus unknownNCT02571829Phase 2Report a problem
• Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011CompletedNCT02431481Phase 1Report a problem
• Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and NeckTerminatedNCT02429089Phase 1Report a problem
• Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011CompletedNCT02388620Phase 1Report a problem
• Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic GliomaStatus unknownNCT02345824Phase 1Report a problem
• A Phase I Study of LEE011 in Asian PatientsCompletedNCT01898845Phase 1Report a problem
• A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.CompletedNCT01237236Phase 1Report a problem

← Ribociclib